DNA X, Inc.

DNA X, Inc. (the “Company”) is unable to file, without unreasonable effort or expense, its Quarterly Report on Form 10-Q for the three months ended June 30, 2026 (the “Form 10-Q”) within the prescribed time period. This delay resulted primarily from accounting for the sale of convertible debt during the period and from the complexities associated with accounting for variable interest entities under Accounting Standards Codification (“ASC”) Topic 810, Consolidation . As reported in the Company’s Current Report on Form 8-K filed with the Securities and Exchange Commission on May 27, 2026 (the “Termination Date”), the Company entered into an Amendment No. 1 to Membership Interest Purchase Agreement with DNA Holdings Venture, Inc. (“DNA Holdings”) that effected the termination of a put option granted to DNA Holdings that afforded DNA Holdings the right to reacquire from the Company all of the Company’s equity interests in its wholly owned subsidiary DNA X, LLC (the “Put Right Termination”). As a result of the Put Right Termination, the Company has determined that, as of the Termination Date, DNA X, LLC is fully controlled and is required under GAAP to be consolidated with the financial statements of the Company. All of the foregoing has required additional time to complete the Company’s financial close process for the three months ended June 30, 2026. The Company has been working diligently to complete the presentation of the new transactions and the consolidation of DNA X, LLC and expects to file the Form 10-Q on or before the fifth calendar day following the prescribed due date

DNA X, Inc. (the “Company”) is unable to file, without unreasonable effort or expense, its Quarterly Report on Form 10-Q for the three months ended March 31, 2026 (the “Form 10-Q”) within the prescribed time period. This delay resulted primarily from the disposition of the Company’s legacy mobile phone and hotspot business (the “Legacy Business”), the closing of which occurred during the first quarter of 2026. In accordance with Accounting Standards Codification 205-20, Discontinued Operations, the Company is required to present the results of the Legacy Business as a discontinued operation in its condensed consolidated financial statements for the three months ended March 31, 2026. The accounting treatment requires, among other things, the separation of the Legacy Business’s results from continuing operations for the current period, the retrospective recasting of all prior period comparative financial statements to present the Legacy Business as a discontinued operation, the determination of the gain or loss on disposition, and income taxes between continuing and discontinued operations. The complexity of this discontinued operations accounting, combined with the need to ensure the accuracy and completeness of the retrospective recasting of prior periods, has required additional time to complete the Company’s financial close process for the quarter ended March 31, 2026. The Company has been working diligently to complete the discontinued operations presentation and expects to file the Form 10-Q on or before the fifth calendar day following the prescribed due date

The Registrant is unable to file, without unreasonable effort or expense, its Annual Report on Form 10-K for the period ended December 31, 2025 (the “Form 10-K”) within the prescribed time period. This delay resulted primarily from the acquisition of the DNA X trading platform, the closing of which occurred during the fourth quarter of 2025. The Registrant is compiling the required information to complete the Annual Report and the audit of the financial statements to be included in the Annual Report. The Registrant remains committed to completing the filing as expeditiously as possible and expects to file the Form 10-K within the fifteen-calendar-day grace period provided by Rule 12b-25